People: Dyax Corp (DYAX.W)

Summary

Name	Age	Since	Current Position
Henry Blair	68	2009	Chairman of the Board
Gustav Christensen	64	2009	President, Chief Executive Officer, Director
George Migausky	57	2008	Chief Financial Officer, Executive Vice President
Burt Adelman	60	2013	Chief Medical Officer, Executive Vice President - Research and Development
Mary Gray	59	2008	Lead Independent Director
Ronald Cohen	56	2011	Independent Director
James Fordyce	69	1995	Independent Director
Thomas Kempner	84	1995	Independent Director
Marc Kozin	50	2012	Independent Director
David McLachlan	74	1999	Independent Director
Paolo Pucci	52	2011	Independent Director
Jennifer Harsey			Manager - Investor Relations and Corporate Communications

» Insider Trading

Biographies

Name	Description
Henry Blair	Mr. Henry E. Blair is Chairman of the Board of Dyax Corp. He served as Chief Executive Officer of Dyax from 1997 through 2008 and has also served as its Chairman of the Board since the merger with Protein Engineering Corporation in 1995. Mr. Blair has over thirty years of experience working in the biopharmaceutical industry. In addition to Dyax, he co-founded Genzyme Corporation. His enzyme replacement therapy research for Gaucher disease, while he was working at Tufts University School of Medicine, was largely responsible for Genzyme’s first therapeutic program and flagship product, Cerezyme®. He also co-founded Biocode, Inc. and GelTex Pharmaceuticals, Inc. Additionally, Mr. Blair has previously served on several public companies’ boards, particularly during their start-up phases, including GTC Biotherapeutics, Inc., Esperion Therapeutics, Inc., Celtrix Pharmaceuticals, Inc. and DynaGen, Inc. In addition to these directorships, Mr. Blair has served on the board of overseers at Tufts University School of Medicine and the Lahey Hitchcock Clinic and was a trustee of the Harvard-affiliated Center for Blood Research, Inc. (now the Immune Disease Institute).
Gustav Christensen	Mr. Gustav A. Christensen is President, Chief Executive Officer, Director of Dyax Corp., since January 2009. From April 2008 through December 2008, Mr. Christensen served as Executive Vice President and Chief Business Officer of Dyax, where he oversaw the Company’s partnering strategy as well as other business development activities such as licensing and collaboration transactions. Previously, Mr. Christensen was Managing Director of Apeiron Partners, LLC, a boutique life sciences investment bank, from 2005 to 2008. He began his career as General Manager at Baxter Travenol Laboratories and left in 1983 to become the Vice President of Business Development at Genetics Institute Inc. from 1983 to 1988. Additionally, he has been the CEO or senior manager of several biopharmaceutical firms. Mr. Christensen received his Master of Science in Economics from the University of Aarhus (Denmark) and his Master of Business Administration from Harvard Business School.
George Migausky	Mr. George V. Migausky is Chief Financial Officer, Executive Vice President of Dyax Corp., since August 2008. He is responsible for financial and administrative operations at Dyax. Prior to joining Dyax, Mr. Migausky served as CFO of Wellstat Management Company, a privately-held company responsible for the strategy, business development and operations of an affiliated group of five life science companies. From 1990 to 2004, he served as CFO at IGEN International where he was instrumental in preparing the Company for its initial public offering in 1994, its merger with F. Hoffman La Roche in 2004 and the simultaneous spinoff of BioVeris Corporation as an independent public company. He served as CFO of BioVeris through to 2008. Mr. Migausky received an MBA from Babson College and a BS from Boston College.
Burt Adelman	Dr. Burt A. Adelman, M.D., is Chief Medical Officer, Executive Vice President - Research and Development of Dyax Corp. Dr. Adelman began his career with Biogen Idec (then Biogen) in 1991 as Director of Medical Research, and held positions of increasing responsibility including Vice President, Regulatory Affairs, Vice President, Development Operations, and Executive Vice President, Research and Development. He retired from Biogen Idec as Executive Vice President of Portfolio Strategy in 2007. Since 1991, Dr. Adelman has served as a lecturer in medicine at the Harvard Medical School. He was also a faculty member in the Department of Medicine at the Medical College of Virginia from 1984 to 1991, and Chief of the Hematology-Oncology service at the Hunter Holmes McGuire VA Medical Center. From 2009 to 2010, Dr. Adelman was interim President of Research and Development at Eleven Biotherapeutics, Inc. From 2010 to present, Dr. Adelman has served as an advisor to Eleven Biotherapeutics, Inc.
Mary Gray	Dr. Mary Ann Gray, Ph.D., is Lead Independent Director of Dyax Corp., since 2008. Dr. Gray established Gray Strategic Advisors, LLC in August 2003 to provide strategic advice to both public and private biotechnology companies. From 1999 to July 2003, she served as a Senior Analyst and Portfolio Manager of the Federated Kaufmann Fund, focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell-side biotechnology analyst with Kidder Peabody, and held similar positions with Warburg Dillon Read and with Raymond James & Associates. Additionally, Dr. Gray has over twelve years of experience as a scientist in academia and industry. She held scientific positions at Schering Plough Corporation and NeoRx Corporation, and early in her career Dr. Gray managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute. She also serves as a director of Acadia Pharmaceuticals, Inc., and Senomyx, Inc., both biotechnology companies.
Ronald Cohen	Dr. Ron Cohen, M.D., has been appointed as Independent Director of Dyax Corp., effective November 01, 2011. Dr. Cohen has been President and Chief Executive Officer of Acorda Therapeutics, Inc. since the company was founded in 1995. Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons and is Board Certified in Internal Medicine. Dr. Cohen previously was a Director and Chairman of the New York Biotechnology Association. He currently serves as a member of the Executive Committee and as Chairman of the Emerging Company Section of the board of the Biotechnology Industry Organization (BIO). He also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council.
James Fordyce	Mr. James W. Fordyce is Independent Director of Dyax Corp., since August 1995. Since 2001 Mr. Fordyce has been Managing Partner of MEDNA Partners LLC, a private advisory firm. From 1981 to 2004 he was a general partner of Prince Ventures LP, a venture capital management firm focused on investments in medicine and the life sciences. He is currently a member of the Board of Directors of several privately-held companies and is Chairman Emeritus of the Board of Directors of the Albert and Mary Lasker Foundation.
Thomas Kempner	Mr. Thomas L. Kempner is Independent Director of Dyax Corp., since August 1995. Previously he was a director of Protein Engineering Corporation before it merged with Biotage and the combination was renamed Dyax. Mr. Kempner has been Chairman and Chief Executive Officer of Loeb Partners Corporation, an investment banking firm, and its predecessors since 1978. He is also President of Pinpoint Partners Corporation, the general partner of the Loeb Investment Partnerships. Mr. Kempner is a director of IGENE BioTechnology, Inc., and Intersections, Inc.
Marc Kozin	Mr. Marc Kozin has been appointed as Independent Director of Dyax Corp. For 15 years, Mr. Kozin was North American President of L.E.K. Consulting, a global management consulting firm that uses deep industry and analytical rigor to help clients solve their most critical business problems. Mr. Kozin led the development of L.E.K.'s biopharmaceutical & life sciences practice, where he advised biopharmaceutical leaders on strategic issues facing their organizations, including, acquisition opportunities and target screening, licensing and joint ventures, portfolio optimization, product planning and commercialization, and domestic and global marketing strategies. Mr. Kozin also serves on the boards of Endocyte, Medical Simulation Corporation, UFP Technologies, CrunchTime! Information Systems, Inc. and DukeEngage. Mr. Kozin received his B.A., magna cum laude, in Economics from Duke University and an M.B.A. with distinction from The Wharton School of the University of Pennsylvania.
David McLachlan	Mr. David J. McLachlan is Independent Director of Dyax Corp., since May 1999. He was the Executive Vice President and Chief Financial Officer of Genzyme Corporation from 1989 to 1999 and a senior advisor to Genzyme’s chairman and chief executive officer through June 2004. Prior to joining Genzyme, Mr. McLachlan served as Chief Financial Officer and Vice President of Adams-Russell Company, an electronic component supplier and cable television operator. Mr. McLachlan currently serves on the Board of Directors of HearUSA Inc., a hearing care company, Deltagen, Inc., a provider of research tools for drug discovery efforts in the biopharmaceutical industry, and Skyworks Solutions, Inc., a manufacturer of analog, mixed signal and digital semiconductors for mobile communications.
Paolo Pucci	Mr. Paolo Pucci has been appointed as Independent Director of Dyax Corp., effective November 01, 2011. Mr. Pucci has served as Chief Executive Officer and a member of the Board of Directors of ArQule, Inc. since 2008. Prior to joining ArQule, Mr. Pucci was a senior vice president and president in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Unit of Bayer A.G. Previously, Mr. Pucci was senior vice president of Bayer Pharmaceuticals Global Specialty Business Unit, president of U.S. Pharmaceutical Operations and a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci joined Bayer as head of its Italian Pharmaceutical operations in 2001. Prior to Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci holds an MBA from the University of Chicago and is a graduate of the Universita Degli Studi Di Napoli in Naples, Italy.
Jennifer Harsey

Basic Compensation

Name	Fiscal Year Total
Henry Blair	1,459,040
Gustav Christensen	1,538,150
George Migausky	717,333
Burt Adelman	--
Mary Gray	--
Ronald Cohen	--
James Fordyce	--
Thomas Kempner	--
Marc Kozin	--
David McLachlan	--
Paolo Pucci	--
Jennifer Harsey	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Henry Blair	692,300	726,852
Gustav Christensen	0	0
George Migausky	0	0
Burt Adelman	0	0
Mary Gray	0	0
Ronald Cohen	0	0
James Fordyce	0	0
Thomas Kempner	0	0
Marc Kozin	0	0
David McLachlan	0	0
Paolo Pucci	0	0
Jennifer Harsey	0	0

Insider Trading

Name	Shares Traded	Price
KOZIN MARC D	5,000	$2.47
KOZIN MARC D	5,000	$2.50
KOZIN MARC D	2,971	$2.45
KOZIN MARC D	800	$2.44
KOZIN MARC D	4,200	$2.41
KOZIN MARC D	5,000	$2.47
MAGOVCEVIC - LIEBISCH IVANA	12,083	$1.48
MAGOVCEVIC - LIEBISCH IVANA	7,860	$4.00
MAGOVCEVIC - LIEBISCH IVANA	3,021	$4.01
MAGOVCEVIC - LIEBISCH IVANA	204,478	$4.00
MAGOVCEVIC - LIEBISCH IVANA	67,291	$1.91
MAGOVCEVIC - LIEBISCH IVANA	128,125	$2.39
MIGAUSKY GEORGE V	4,275	$3.28
MAGOVCEVIC - LIEBISCH IVANA	4,015	$3.24
KEMPNER THOMAS L	1,417	$3.46
KEMPNER THOMAS L	3,075	$3.47
MCLACHLAN DAVID J	23,638	$1.99
MCLACHLAN DAVID J	23,638	$3.09
MCLACHLAN DAVID J	153	$3.10
MCLACHLAN DAVID J	3,209	$3.11
MCLACHLAN DAVID J	3,362	$1.99
BLAIR HENRY E	30,000	$1.36
CHRISTENSEN GUSTAV A	600	$1.53
CHRISTENSEN GUSTAV A	4,400	$1.52
CHRISTENSEN GUSTAV A	100	$1.42

» Full list on Insider Trading

People: Dyax Corp (DYAX.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: